Skip to main content

Table 2 Carriage prevalence per 100 children, overall and by vaccine-type and non-vaccine type, in 2015

From: Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13

VariableNumber of carriers per subgroupPrevalence carriage, per 100 children [95%CI]Prevalence PCV7a carriage number; prevalence per 100 children [95%CI]Prevalence PCV13–7b carriage number; prevalence per 100 children [95%CI]Prevalence NVTc carriage number; prevalence per 100 children [95%CI]
Total43148.1 [43.7–52.5]12; 1.3 [0.7–2.4]13;1.5 [0.8–2.6]412; 46.0 [41.5–50.5]
Age in months431 included    
< 24 months8460.4 [52.2–68.1]0; 0 [NA]1; 0.72 [0.09–5.4]84; 60.4 [52.2–68.1]
24–35 months9456.0 [48.1–63.6]2; 1.2 [0.28–5.0]1; 0.60 [0.08–4.4]91; 54.2 [46.0–62.1]
36–47 months10553.9 [46.0–61.5]4; 2.0 [0.61–6.7]6; 3.0 [1.5–6.1]98;50.3 [42.8–57.7]
48–59 months8942.8 [35.5–50.5]2; 0.96 [0.25–3.6]5; 2.4 [0.85–6.6]84; 40.4 [33.0–48.3]
> = 60 months5931.7 [24.6–39.8]4; 2.2 [0.83–5.5]0; 0 [NA]55; 29.6 [22.8–37.4]
Vaccinated by type428 included    
PCV72034.5 [22.9–48.3]1; 1.7 [0.22–12.1]0; 0 [NA]19; 32.8 [21.1–47.0]
PCV7+135230.1 [23.0–38.3]2; 1.2 [0.28–4.7]1; 0.58 [0.08–4.1]49; 28.3 [21.7–36.9]
PCV1335454.5 [50.0–58.9]8; 1.2 [0.54–2.8]12; 1.9 [0.98–3.5]340; 52.3 [47.7–56.9]
Unvaccinated240.0 [11.1–78.0]1; 20.0 [6.7–46.7]0; 0 [NA]1; 20.0 [6.7–46.7]
Having used antimicrobials the past 3 months428 included    
Yes2840.6 [30.9–51.1]0; 0 [NA]0; 0 [NA]28; 40.6 [30.9–51.1]
No40048.5 [44.0–53.1]12; 1.5 [0.80–2.6]12; 1.5 [0.78–2.7]382; 46.4 [41.7–51.1]
  1. acarriage of serotypes covered by the 7-valent pneumococcal conjugate vaccine
  2. bcarriage of serotypes covered by the 13-valent pneumococcal conjugate vaccine but not by the 7-valent vaccine
  3. ccarriage of serotypes not covered by the 13-valent pneumococcal conjugate vaccine
  4. NA not applicable (the 95% could not be determined because  no children in this category carried these types)